SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
SEC Accession No. 0000950144-01-507050
Filing Date
2001-09-19
Accepted
2001-09-19 00:00:00
Documents
7

Document Format Files

Seq Description Document Type Size
1 NOVAVAX, INC. / KING PHARMACEUTICALS, INC. g71340a1sc13da.txt SC 13D/A 31094
3 CONVERTIBLE NOTE NO. 2 g71340a1ex4.txt EX-4 29503
4 CONVERTIBLE NOTE NO. 3 g71340a1ex5.txt EX-5 29526
5 ALLONGE TO 4% CONVERTIBLE SENIOR NOTE g71340a1ex6.txt EX-6 6738
6 AMENDMENT TO INVESTOR RIGHTS AGREEMENT g71340a1ex7.txt EX-7 7038
7 AMENDED AND RESTATED REGISTRATION RIGHTS AGREEMENT g71340a1ex8.txt EX-8 62656
8 SEPTEMBER 2001 NOTE PURCHASE AGREEMENT g71340a1ex9.txt EX-9 56464
  Complete submission text file 0000950144-01-507050.txt   225457
Mailing Address 8320 GUILFORD ROAD SUITE C 12111 PARKLAWN DR COLUMBIA MD 21046
Business Address 8320 GUILFORD RD STE C COLUMBIA MD 21046 3078543900
NOVAVAX INC (Subject) CIK: 0001000694 (see all company filings)

IRS No.: 222816046 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D/A | Act: 34 | File No.: 005-48948 | Film No.: 1740456
SIC: 2836 Biological Products, (No Diagnostic Substances)

Mailing Address 501 FIFTH ST BRISTOL TN 37620
Business Address 501 FIFTH ST BRISTOL TN 37620 4239898000
KING PHARMACEUTICALS INC (Filed by) CIK: 0001047699 (see all company filings)

IRS No.: 541684963 | State of Incorp.: TN | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations